11099 N. Torrey Pines Rd. Suite 290
5 articles with Janux
Janux Therapeutics, Inc. today announced the appointment of Shahram Salek-Ardakani, Ph.D., as Chief Scientific Officer.
Janux Therapeutics Announces Closing of Initial Public Offering and Full Exercise of Underwriters’ Option to Purchase Additional Shares
Janux Therapeutics, Inc. today announced the closing of its previously announced initial public offering of 13,110,000 shares of its common stock.
Janux Therapeutics, Inc., a biopharmaceutical company developing novel T cell engager immunotherapies, announced the pricing of its initial public offering of 11,400,000 shares of its common stock at a price to the public of $17.00 per share.
The last few weeks have seen a flurry of filings for initial public offerings by biotech companies. Here’s a look.
Janux Therapeutics, a biopharmaceutical company developing novel T cell engager immunotherapies, today announced the appointment of Wayne Godfrey, M.D., as Chief Medical Officer, effective June 1, 2021.